Additional file 2 of Relationships of 18F-FDG PET with tumor microenvironment immunotypes, especially PD-L1 and CD15 expression, and prognosis in oral squamous cell carcinoma

Additional file 2. Figure S2. Scatter plots presenting the correlation between CD15 and S100A8 and between FDG uptakeand CD15, programmed death ligand-1, S100A8, and tumor size

Additional file 3 of Relationships of 18F-FDG PET with tumor microenvironment immunotypes, especially PD-L1 and CD15 expression, and prognosis in oral squamous cell carcinoma

Additional file 3. Table S1. Correlation between FDG-PET and pathological data

Additional file 1: of Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index

Results of a multivariate survival analysis on the influence of clinicopathological variables including PgR in the intermediate Ki67 labeling index group. (PDF 118 kb

Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer

<div><p>The preoperative endocrine prognostic index (PEPI) predicts survival after neoadjuvant endocrine therapy (NAE) using aromatase inhibitors (AIs) for women with postmenopausal estrogen receptor (ER)-positive breast cancer irrespective of the human epidermal growth factor receptor 2 (HER2) status. Although the progesterone receptor (PgR) is also a prognostic factor for ER-positive breast cancer, the PgR status was not considered a prognostic factor in the original PEPI scoring system. In this study, we investigated the utility of a modified PEPI including the PgR status (PEPI-P) as a prognostic factor after NAE for postmenopausal patients with ER-positive and HER2-negative breast cancer. We enrolled 107 patients with invasive ER-positive and HER2-negative breast cancer treated with exemestane for ≥4 months as NAE. We initially assessed PEPI and compared survival between the groups. Additionally, we obtained an effective cutoff for PgR through survival analysis. Then, we assessed the survival significance of PEPI-P. A PgR staining rate of 50% was the most significant cutoff for predicting recurrence-free survival (RFS) and cancer-specific survival (CSS). PEPI was a significant prognostic factor; moreover, PEPI-P was the most significant prognostic indicator for RFS and CSS. PEPI-P is a potent prognostic indicator of survival after NAE using AIs for postmenopausal patients with ER-positive and HER2-negative breast cancer. This modified PEPI may be useful for therapeutic decision-making regarding postmenopausal ER-positive and HER2-negative breast cancer after NAE.</p></div

Cumulative survival of patients with breast cancer stratified by our modified PEPI including the primary PgR status (PEPI-P).

<p>Relationships of PEPI-P with (A) recurrence-free (RFS) and (B) cancer-specific survival (CSS).</p

Cumulative survival of patients with breast cancer stratified by the original preoperative endocrine prognostic index (PEPI).

<p>(A) Recurrence-free survival (RFS) was significantly worse in the high PEPI group than in the low PEPI group (<i>P</i> = 0.013). (B) No significant differences were noted in cancer-specific survival (CSS) between the high and low PEPI groups (<i>P</i> = 0.092).</p

Survival analysis of the influence of clinicopathological variables including the preoperative endocrine prognostic index (PEPI) and PEPI combined with the primary PgR status (PEPI-P).

<p>Survival analysis of the influence of clinicopathological variables including the preoperative endocrine prognostic index (PEPI) and PEPI combined with the primary PgR status (PEPI-P).</p

Survival analysis according to the Allred score and PgR staining percentage in primary tumors.

<p>Survival analysis according to the Allred score and PgR staining percentage in primary tumors.</p

Recurrence-free survival (RFS) and cancer-specific survival (CSS) curves for the high (≥50%) and low primary progesterone receptor (p-PgR) (<50%) groups.

<p>RFS and CSS were significantly better in the high p-PgR group than in the low p-PgR group (RFS: <i>P</i> = 0.0053; CSS: <i>P</i> = 0.0031).</p